CBMX,
CombiMatrix Names Nanotechnology Leader F. Mark Modzelewski to Its Scientific Advisory Board
--------------------------------------------------------------------------------
Mon Feb 02 07:00:00 2004 EST
NEWPORT BEACH, Calif., Feb 2, 2004 (BUSINESS WIRE) --
Acacia
Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that
its CombiMatrix group has named F. Mark Modzelewski to its Scientific
Advisory Board. Mr. Modzelewski is the founder and Executive Director
of the Nanobusiness Alliance (www.nanobusiness.org).
Mr. Modzelewski is also a member of the Nanotechnology Technical
Advisory Group to President Bush's Council of Advisors on Science and
Technology (PCAST), was recognized by Forbes magazine as one of
nanotech's 5 "powerbrokers," and he has testified before the U.S.
Senate on nanotechnology funding, investment, technology transfer and
global competition.
Mr. Modzelewski has taught classes on the business of
nanotechnology at Northwestern's Kellogg School and NYU's Stern School
of Business, and he has lectured before numerous global technology and
investor conferences, leading think tanks, as well as briefing the
White House, US Dept. of Commerce, NSF, Congress, the Federal
Reserve's Financial Markets retreat, global Fortune 500 companies, and
numerous foreign government agencies. He has been featured in Time,
Newsweek, US News, ABC News, CNBC, CNNfn, BBC, Bloomberg Radio,
Forbes, Business Week, Fortune, Wall Street Journal, and Investors
Business Daily.
He has also held positions at various firms including Opion,
Niehaus, Ryan, Wong NYC, and Golin/Harris International. Before
entering the private sector, he was an appointee in the Clinton
Administration, where he served as Special Assistant to Sec. Henry
Cisneros at HUD and Sec. Dan Glickman of USDA. Mr. Modzelewski is a
graduate of the University of Denver College of Law and Boston
University.
"I am impressed with CombiMatrix's technology and capabilities in
the nanotechnology space, as well as its broadly encompassing strategy
for commercialization of its core technology into multiple markets. I
am looking forward to working with the company in the future," said
Mr. Modzelewski.
"Based on Mr. Modzelewski's accomplishments, one can say that he
is truly a visionary in the nanotechnology field," said Dr. Amit
Kumar, President and CEO of CombiMatrix. "We are pleased to have him
join us and provide guidance and advice as we continue to build
CombiMatrix into one of the leaders in the fields of biotechnology and
nanotechnology."
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation comprises two operating groups, Acacia
Technologies Group and CombiMatrix Group.
The CombiMatrix group is developing a platform technology to
rapidly produce customizable active biochips, which are
semiconductor-based tools for use in identifying and determining the
roles of genes, gene mutations and proteins. CombiMatrix's technology
has a wide range of applications including DNA synthesis/diagnostics,
siRNA synthesis, drug discovery, and immunochemical detection.
CombiMatrix provides DNA arrays to researchers under the
CustomArray(TM) brand.
CombiMatrix's Express Track(SM) drug discovery program is a
systems biology approach, using its technology, to target common viral
diseases with siRNA compounds. The initial focus of Express Track(SM)
includes the following viral diseases:
Virus Collaborator
SARS NIAID/USAMRIID
HIV type 1 irsiCaixa-Dr. Bonaventura Clotet
HIV type 2 To Be Announced
West Nile virus To Be Announced
Human Papillomavirus type 16 To Be Announced
Human Herpes 8 (Kaposi's sarcoma) To Be Announced
Smallpox (Variola) To Be Announced
Influenza virus A To Be Announced
Influenza virus B To Be Announced
Hepatitis C To Be Announced
CombiMatrix is also establishing applications of its arrays
through other partnerships as follows:
Project Collaborator
Cancer Diagnosis (Lymphoma) University of Washington/Rational
Diagnostics
RNA Drug Targets Professor Gregory L. Verdine,
Harvard University
Parasite
Leishmania Seattle Biomedical Research
Institute
Trypasonoma Seattle Biomedical Research
Institute
The Acacia Technologies group licenses its Digital Media
Transmission (DMT) technology to media and electronics companies. The
DMT technology covers the transmission and receipt of digital audio
and digital video content, commonly known as audio on-demand, video
on-demand, and audio/video streaming, and is supported by 5 U.S. and
31 foreign patents.
Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia
Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock
issued by Acacia Research Corporation and are intended to reflect the
performance of the respective operating groups and are not issued by
the operating groups.
Information about Acacia Research Corporation and the Acacia
Technologies group is available at www.acaciaresearch.com. Information
about the CombiMatrix group is available at www.combimatrix.com.
SOURCE: Acacia Research Corporation
Acacia Research Corporation, Newport Beach
Bret L. Undem, 425-493-2293
Media Relations
Fax: 425-493-2010
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.
-------------------------------------------------------------------------------- |
